Clinical Trial

TURKAPNE - The Turkish Sleep Apnea Database: A National, Multicenter, Observational, Prospective Cohort Study

Study acronym: TURKAPNE
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated October 13, 2022 (before its estimated December 31, 2024 completion). Its status may not reflect the trial's current state.
Summary
Primary aim of the TURKAPNE (The Turkish Sleep Apnea Database) study is to generate a cross-sectional nationwide database to define clinical and polysomnographic characteristics of the sleep apnea patients in Turkey. Associations of phenotypes of sleep apnea patients with metabolic and cardiovascular diseases as well as risk for traffic accidents will be explored as secondary aims. Impact of treatment of sleep apnea on metabolic and cardiovascular complications as well as compliance with positive airway pressure treatment will be further explored longitudinally.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2016-05-24; most recent amendment 2022-10-12.
Status change: Not Yet Recruiting → Recruiting 2017-10-02
Trial Details
NCT Number NCT02784977
Lead Sponsor Koç University
Collaborators: Ege University School of Medicine, Izmir, Turkey, Dokuz Eylul University, Diskapi Yildirim Beyazit Education and Research Hospital, Uludag University, Dicle University School of Medicine, Diyarbakir, Turkey, Namik Kemal University School of Medicine, Tekirdag, Suleyman Demirel University School of Medicine, Isparta, Turkey, Istanbul University - Cerrahpasa, Pamukkale University School of Medicine, Denizli, Turkey, Trakya University, Afyon Kocatepe University School of Medicine, Afyon, Turkey, Hitit University School of Medicine, Corum, Turkey, Istanbul Sureyyapasa Chest Diseases and Chest Surgery Training and Research Hospital, Kocaeli Education and Research Hospital, Kocaeli, Turkey, Baskent University Ankara Hospital, Marmara University
Conditions Obstructive Sleep Apnea
Enrollment 10,000 participants
Start Date 2017-10-03
Primary Completion 2024-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2022-10-13